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Mitomycin C is one of the most effective chemotherapeutic agents for a wide spectrum of cancers, but its clinical
use is still hindered by the mitomycin C (MMC) delivery systems. In this study, the MMC-loaded polymer-lipid hybrid
nanoparticles (NPs) were prepared by a single-step assembly (ACS Nano 2012, 6:4955 to 4965) of MMC-soybean
phosphatidyhlcholine (SPC) complex (Mol. Pharmaceutics 2013, 10:90 to 101) and biodegradable polylactic acid
(PLA) polymers for intravenous MMC delivery. The advantage of the MMC-SPC complex on the polymer-lipid hybrid
NPs was that MMC-SPC was used as a structural element to offer the integrity of the hybrid NPs, served as a drug
preparation to increase the effectiveness and safety and control the release of MMC, and acted as an emulsifier to
facilitate and stabilize the formation. Compared to the PLA NPs/MMC, the PLA NPs/MMC-SPC showed a significant
accumulation of MMC in the nuclei as the action site of MMC. The PLA NPs/MMC-SPC also exhibited a significantly
higher anticancer effect compared to the PLA NPs/MMC or free MMC injection in vitro and in vivo. These results
suggested that the MMC-loaded polymer-lipid hybrid NPs might be useful and efficient drug delivery systems for
widening the therapeutic window of MMC and bringing the clinical use of MMC one step closer to reality.
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Nanotechnology represents a powerful tool in the field
of medicine to deal with cancer [1,2], which is still a
leading cause of death worldwide [3]. Nevertheless, there
is the limited availability of nanotechnology-based drug
formulation which is approved by FDA in clinical use. It
is a formidable challenge to develop the smarter and bet-
ter nanoscaled drug delivery systems. Up to now, both
lipid-based and polymer-based nanoscaled drug delivery
systems have represented two dominant classes of nanos-
caled drug delivery systems for anticancer drug delivery
and shown promising efficacy for clinical treatment [4-6].
Liposome, one of the most investigated lipid-based car-
riers, is a spherical vesicle composed of lipid material and
has been widely used for drug delivery due to improved
safety profile, high delivery efficiency, favorable pharmaco-
kinetics, and ease of surface modification [7]. However,
their clinical uses by intravenous injection are significantly* Correspondence: xly885@163.com
†Equal contributors
5The First Affiliated Hospital of Xiamen University, Xiamen 361003, China
Full list of author information is available at the end of the article
© 2014 Yi et al.; licensee Springer. This is an op
Attribution License (http://creativecommons.or
in any medium, provided the original work is plimited because of the insufficient drug loading, burst drug
release, instability, and toxicity. Polymeric nanoparticles
(NPs), one of the most investigated polymer-based car-
riers, have small particle size, ability to load drug of poor
solubility and permeability, appropriate physiological
stability, well-storage stability, controlled and sustained
drug release, and long systemic circulation time [5,8]. In
addition, the preparation of polymeric NPs by nanopre-
cipitation or emulsion is simple and scalable [9]. How-
ever, the biocompatibility of the polymeric NPs formed
by most synthetic polymers is not as high as the lipo-
somes, especially at the cellular and animal level. Thus, it
is necessary to develop a novel and practical drug carrier
which can combine the desired advantages and avoid the
undesired disadvantages of both the lipid-based and
polymer-based carriers for clinical application [10].
In recent years, the polymer-lipid hybrid NPs designed
to merge the best of both worlds had been reported in
several groups. The first was that the polymer-lipid hybrid
NPs were prepared via the fusion of the polymeric NPs
and liposomes [11]. The preparation of the polymer-lipid
core-shell structure usually required a two-step process:en access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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capsulation of the liposomes [8,12]. However, the process
resulted in the technical complexity and the poor control
over the final characteristics of the nanoscaled drug deliv-
ery systems [8,13]. The second was that the polymer-lipid
hybrid NPs were prepared by a single step which com-
bined the nanoprecipitation (or emulsion) and self-
assembly method [14,15]. The strategy satisfied the
need for the development of precise and predictable
hybrid nanoscaled drug delivery systems, which would
be convenient for future scaling-up.
Mitomycin C (MMC) is a water-soluble anticancer and
antibiotic agent by inhibiting DNA synthesis and nuclear
division and has been extensively used to treat various
cancer including stomach, liver, breast, pancreas, colon,
and bladder cancers [16]. MMC was a very poor substrate
for P-glycoprotein and retained activity against many types
of P-glycoprotein-mediated multidrug resistant tumor
cells [17,18]. However, a major concern of MMC was in
the narrow therapeutic index and serious side effects
such as severe myelosuppression and gastrointestinal
complications [19,20]. Recently, the drug-phospholipid
complex had received significant attention [21,22] because
of the significant improvement of drug efficacy and safety
[23-30]. To address the issue, we prepared the MMC-
soybean phosphatidyhlcholine complex (MMC-SPC com-
plex) to increase the effectiveness of MMC [31]. On the
one hand, MMC interacted with soybean phosphatidyl-
choline (SPC) via the non-covalent bonds and resulted in
almost 100% complexation efficiency. On the other hand,
the amphiphilic character of the drug-phospholipid com-
plex could promote the passive transport from the water
environment to the lipid-rich cell membrane to increase
the drug permeability and enhance the drug bioavailability
and improve the drug effectiveness [32].
Previously Wang et al. prepared the polymer-lipid hy-
brid NPs for systemic delivery of small interfering RNA
(siRNA) [13]. In this study, to develop the hybrid nanos-
caled drug delivery systems that complemented and inte-
grated the characteristics of polymeric NPs and liposomes
for systemic MMC delivery, we continued to use theFigure 1 Schematic illustration of the hybrid PLA NPs/MMC-SPC prepMMC-SPC complex [31] to prepare the MMC-loaded
polymer-lipid hybrid NPs by a single-step assembly of
polylactic acid (PLA) and MMC-SPC complex (Figure 1).
PLA, one of the FDA approved biodegradable polymers
for clinical applications, had been demonstrated to be safe
in vivo for several decades. SPC had always been regarded
as a promising candidate for drug preparations due to the
biocompatibility, biodegradability, metabolic activity, and
low toxicity and cytotoxicity compared to synthetic alter-
natives [31,33,34]. Most significantly of all, some advan-
tages of the drug-phospholipid complex on the basis of
the PLA NPs were as follows. Firstly, the MMC-SPC com-
plex was used as a structural element, which could inte-
grate the best of both polymer and lipid worlds and offer
the integrity of the hybrid polymer-lipid nanoscaled drug
delivery system. Secondly, the MMC-SPC complex was
served as a drug preparation to link the conventional and
novel drug formulation, which could increase the lipophi-
licity, storage stability, efficacy and safety, and control the
release of MMC for systemic drug delivery. Lastly, the
MMC-SPC complex was acted as a stabilizer/emulsifier
to facilitate and stabilize the formation of the nanos-
caled drug delivery systems. The advantages of the SPC-
emulsified nanoscaled drug delivery systems over those
emulsified by the traditional chemical emulsifier poly
(vinyl alcohol) (PVA) were investigated. The physico-
chemical characterizations of the PLA NPs/MMC-SPC
were performed by in vitro drug release, and in vitro




All chemical reagents were of analytical grade and used
without further purification unless otherwise stated. Mito-
mycin C (MMC; purity grade = 99.5%) was purchased
from Hisun Pharmaceutical Co., Ltd. (Zhengjiang, China).
SPC was provided by Lipoid GmbH (Ludwigshafen,
Germany). Poly(D,L-lactide) (PLA; 10 kDa) was provided
by Daigang BIO Engineer Co., Ltd. (Shandong, China).
N,N-dimethylformamide (DMF), 3-(2-benzothiazolyl)-N,ared through a single-step method and their drug delivery.
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5-isothiocyanate (FITC), and Dulbecco's modified Eagle's
medium (DMEM) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Iodide [1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindotricarbocyanine iodide (DiR) was provided
by Molecular Probes Inc. (Eugene, OR, USA). A dialy-
sis bag (Mw = 8, 000 to 14, 000 Da) was ordered from
Greenbird Inc. (Shanghai, China). Deionized (DI) water
was used throughout. Fetal bovine serum (FBS) was
purchased from Gibco Life Technologies (AG, Zug,
Switzerland). Trypsin-EDTA (0.25%) and penicillin-
streptomycin solution were from Invitrogen (Life
Technologies, Basel, Switzerland). All solvents used in
this study were high-performance liquid chromatography
(HPLC) grade. Mouse hepatoma cell line H22 cells were
provided by the Cell Bank at the China Academy of
Science.
Preparation of PLA NPs/MMC-SPC
Firstly, MMC and SPC were added to tetrahydrofuran
by vigorous agitation in a 40°C water bath for 4 h [31].
The organic solvent was evaporated under reduced pres-
sure. The MMC-SPC loaded PLA NPs (PLA NPs/MMC-
SPC) were prepared by a facile dialysis method. Twenty
milligrams of PLA and the weighed amount of MMC-
SPC (the weight ratio of MMC and SPC was 1:2) were
dissolved in 10 mL of DMF accompanied by vigorous
stirring, and then, the resulting organic phase was intro-
duced into a dialysis bag. Subsequently, the dialysis bag
was placed into 1,000 mL of DI water as the aqueous
phase under moderate agitation. The organic phase was
dialyzed against the aqueous phase for 8 h [35], after
that, the suspensions were filtered through a 450 and
200 nm polycarbonate membrane (Millipore, Bedford,
MA, USA), respectively. Then, the PLA NPs/MMC-SPC
were collected by centrifugation with a JA-20 rotor
(Beckman Coulter, Inc., Fullerton, CA, USA) at 15,000
rpm at 4°C for 10 min, after that, the PLA NPs/MMC-
SPC were resuspended in DI water. The PLA NPs/MMC
were prepared by a double emulsion solvent-evaporation
technique for comparison. PLA was added into 10 mL
of DMF to form the oil phase, and MMC was added into
5 mL of DI water to form the inner water phase. The
inner water phase was mixed with the oil phase under
stirring and then, the mixture was sonicated in an ice
water bath to form a primary emulsion. The primary
emulsion was added into DI water with 2% (w/v) PVA
and homogenized at of 1,000 rpm.
In addition, the micron-sized PLA NPs/MMC-SPC
(used for confocal laser scanning microscopy image)
could be formulated as follow: FITC conjugated MMC
(FITC-MMC; FITC-MMC was synthesized based on the
reaction between MMC and FTIC via a thiourea linkage)
was prepared for use as a fluorescence probe. And then,FITC-MMC-SPC complex was prepared in a same way as
described above. Thirty-six milligrams of FITC-MMC-
SPC complex and 200 mg of PLA were dissolved in
10 mL of DMF, accompanied by vigorous stirring. The
mixture was dialyzed against 1,000 mL of DI water for
8 h. Then, the micron-sized PLA NPs/FITC-MMC-SPC
were collected by centrifugation at 15,000 rpm at 4°C for
10 min, after that, the micron-sized PLA NPs/FITC-
MMC-SPC were resuspended in DI water.
Drug encapsulation efficiency and drug loading content
For determination of drug encapsulation efficiency and
drug loading content, the lyophilized PLA NPs/MMC-
SPC were dissolved in DMF. The organic solution was
filtered and submitted to HPLC analysis. The amount of
MMC was assayed using a HPLC (Waters Corporation,
Milford, MA, USA) system consisting of a Waters 2695
Separation Module (Waters Corporation, Milford, MA,
USA) and a Waters 2996 Photodiode Array Detector
(Waters Corporation, Milford, MA, USA) with the fol-
lowing conditions: chromatographic column, symmetry
C18 column (250 × 4.6 mm, 5 μm); temperature, 25°C;
and elution flow rate, 1.0 mL/min. The mobile phase for
the determination of MMC was water-methanol (65/35,
v/v). The detection wavelength for the determination of
MMC was 362 nm. The drug encapsulation efficiency
and drug loading content were calculated according to
the formula
Drug encapsulation efficiency %ð Þ
¼ ðthe weight of the loaded drug
=the weight of the input drugÞ  100%
Drug loading content %ð Þ
¼ ðthe weight of the loaded drug
=the weight of the NPsÞ  100%
Characterization of PLA NPs/MMC-SPC
The average particle size, polydispersity index (PDI), and
zeta potential of the suspension of the PLA NPs/MMC-
SPC were performed by dynamic light scattering (DLS)
using a Malvern Zetasizer Nano-ZS (Malvern Instruments,
Worcestershire, UK). Particle size was evaluated by
intensity distribution. The morphology of the PLA
NPs/MMC-SPC was visualized by SEM (LEO 1530VP,
Oberkochen, Germany) operating at 20 kV and TEM
(JEM 1400, JEOL, Tokyo, Japan) operating at 200 kV.
In vitro stability tests
The lyophilized PLA NPs/MMC-SPC were suspended in
phosphate buffer solution (PBS) (pH 7.4) and incubated
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intervals by DLS.
In vitro drug release
The release of MMC from the PLA NPs/MMC-SPC was
determined by a dialysis technique. The lyophilized NPs
were dispersed in 3 mL of PBS (1/15 M, pH 7.4) buffer
solution. The dispersions were transferred to a dialysis
bag (Mw = 8,000 to 14,000 Da) and then subjected to
dialysis against 10 mL of PBS at 37°C. At a predesigned
time interval, all of the PBS buffer solution was with-
drawn and subsequently replaced with the 10 mL of
fresh PBS after each sampling. The PLA NPs/MMC and
free MMC were used for comparison. The release of
MMC was determined by a HPLC method as described
above.
Cell culture
H22 cells (mouse hepatoma cell line) were cultured in
DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin. The cells were cultivated in a humidified
atmosphere containing 5% CO2 at 37°C.
In vitro cellular uptake
To facilitate the observation of cellular uptake, coumarin-
6 was used as a hydrophobic fluorescence probe [36] to
load within the PLA NPs/MMC-SPC and PLA NPs/
MMC, respectively (designed as the coumarin-6-PLA
NPs/MMC-SPC and coumarin-6-PLA NPs/MMC, respect-
ively). H22 cells were seeded at a density of 1 × 10
5 cells per
well in 6-well plates with their specific cell culture medium.
The cells were incubated at 37°C and 5% CO2 for 24 h.
One-hundred microliters of the coumarin-6-PLA NPs/
MMC-SPC and coumarin-6-PLA NPs/MMC at the
equivalent coumarin-6 concentration was added and
incubated further for 6 h. The cells were washed with
PBS, fixed with 4% paraformaldehyde, and stained with
Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA).
The cells were observed using a Leica TCS SP5 con-
focal laser scanning microscopy (Leica Microsystems,
Mannheim, Germany).
Flow cytometry
To further quantitatively investigate the cellular uptake,
coumarin-6 was used as a fluorescence probe to load
within the PLA NPs/MMC-SPC and PLA NPs/MMC,
respectively (designed as the coumarin-6-PLA NPs/
MMC-SPC and coumarin-6-PLA NPs/MMC, respect-
ively). H22 cells were seeded in 6-well plates with a dens-
ity of 2 × 105 cells/mL and incubated for 24 h, and then,
the original medium was replaced with the coumarin-
6-PLA NPs/MMC-SPC and coumarin-6-PLA NPs/MMC-
SPC at the equivalent coumarin-6 concentration. The cells
were incubated for the predesigned time at 37°C and thenwashed with cold PBS and harvested by 0.25% trypsin-
EDTA. The harvested cells were suspended in PBS and
centrifuged at 1,000 rpm for 5 min at 4°C. After washing
and centrifugation, the cells were resuspended in PBS and
performed by a Beckman Coulter EPICS XL flow cyt-
ometer (Beckman Coulter, Fullerton, CA, USA).
Intracellular drug delivery
To understand the intracellular distribution of the drug
inside H22 cells, FITC conjugated MMC (FITC-MMC;
FITC-MMC was synthesized based on the reaction be-
tween MMC and FTIC via a thiourea linkage [37]) was
prepared for use as a fluorescence probe. H22 cells were
incubated for 24 h and then cultured with the PLA NPs/
FITC-MMC-SPC or PLA NPs/FITC-MMC for 12 h at
37°C. The cells were imaged using a confocal laser scan-
ning microscopy. Rhodamine phalloidin was used to stain
cytoskeleton. Hoechst 33258 (Sigma-Aldrich, St. Louis,
MO, USA) was used to stain nuclei.
In vitro cell viability
The cytotoxicity of the drug delivery systems was mea-
sured using a MTT assay (Sigma-Aldrich, St. Louis, MO,
USA) according to the manufacturer's suggested proce-
dures. H22 cells were exposed to the PLA NPs/MMC-SPC,
PLA NPs/MMC or free MMC with different MMC con-
centrations for 24 h. The data were expressed as the
percentage of surviving cells.
In vivo blood circulation
All the animal procedures complied with the guidelines
of the Xiamen University Institutional Animal Care and
Use Committee. The experiments were performed on
adult male SD rat weighing 200 ± 20 g (mean ± SD) from
Shanghai Laboratory Animal Center. DiR was used as a
near-infrared fluorescence probe to load within the PLA
NPs/MMC-SPC and PLA NPs/MMC, respectively [38].
One-hundred microliters of the DiR-PLA NPs/MMC-SPC
and DiR-PLA NPs/MMC at the equivalent DiR concentra-
tion was respectively injected intravenously through the
tail vein of rats. At timed intervals, 200 μL of blood was
collected and stored in heparin containing eppendorf
tubes at 4°C for further analysis. The plasma was sepa-
rated from the blood by centrifuging at 2,000 rpm for
5 min. The plasma was diluted with methanol and centri-
fuged to remove the insoluble solid. At the excitation wave-
length of 748 nm, the fluorescence intensity at 780 nm was
measured using a microplate reader and the corresponding
DiR concentration was calculated according to an estab-
lished standard curve.
In vivo fluorescence imaging
For in vivo imaging, 0.2 mL of the DiR-PLA NPs/MMC-
SPC was injected into the nude mice bearing H22 tumor
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and 12 h after injection using a Maestro™ in vivo im-
aging system (Cambridge Research & Instrumentation,
Woburn, MA, USA). At 12 h post-injection, the mice
were sacrificed. The tumor and normal tissues (tumor,
liver, spleen, lung, kidney, and heart) were excised,
followed by washing the surface with 0.9% NaCl for the
ex vivo imaging of DiR fluorescence using a Maestro™ in vivo
imaging system (Cambridge Research & Instrumentation,
Woburn, MA, USA). The mice treated without 0.2 mL of
the DiR-PLA NPs/MMC-SPC were used for comparison.
In vivo anticancer effect
Kunming mice aged 4 to 5 weeks (clean class, 18 to 22 g)
were supplied by Xiamen University Laboratory Animal
Center and used in this study. Subcutaneous tumors were
established in the mice by subcutaneous inoculation of
5 × 106 H22 cells in the right axillary region of the mice
before the treatment. H22 tumors were not hormone
dependent and easily grown in the subcutaneous layer of
mice. The tumors were allowed to grow for 1 week after
tumor transplantation, after that, the treatment was per-
formed. The H22 tumor-bearing mice were randomly di-
vided into 4 groups (10 mice per group): group 1 for 0.9%
NaCl, group 2 for PLA NPs/SPC, group 3 for free MMC
injection, and group 4 for PLA NPs/MMC-SPC. The mice
were intravenously administrated at 4 mg/kg (equivalentFigure 2 Characteristics of the hybrid PLA NPs/MMC-SPC. (A) Particle s
Inset: confocal laser scanning microscopy images of the hybrid PLA NPs/FIT
Scale bar = 500 nm. (D) TEM image. (E) In vitro stability in PBS at 37°C. DataMMC concentration) every 2 days for 3 times. Each
mouse was earmarked and followed individually through-
out the whole experiments. The tumor size and body
weight were then monitored every 2 days. The mice were
euthanized on day 12. The greatest longitudinal diameter
(length) and the greatest transverse diameter (width) of
the tumor were measured using a vernier caliper, and the
tumor volume was calculated using length × width2 × 0.5.
Results and discussion
Preparation and characterization of PLA NPs/MMC-SPC
In this study, a single-step dialysis method by addition of
the amphiphilic MMC-SPC complex to the PLA poly-
mer solution in DMF was used to form the hybrid PLA
NPs/MMC-SPC. DMF is water miscible and a good solv-
ent for the PLA polymer and MMC-SPC complex. PLA
and MMC-SPC were first added to DMF (organic phase)
and were then dialyzed against water (aqueous phase).
After the exchange of the organic phase and the aqueous
phase under continuous dialysis process, the PLA poly-
mer and MMC-SPC complex precipitated to form the
PLA NPs/MMC-SPC with a core-shell structure, and the
amphiphilic MMC-SPC complex was adsorbed and self-
assembled on the surface of the PLA core by hydropho-
bic interaction, as illustrated in Figure 1 (more details
are shown in Figure 2). More importantly, the drug-
phospholipid complex was not only used as a structuralize with particle size distribution. (B) Zeta potential. (C) SEM image.
C-MMC-SPC (FITC was conjugated with MMC via a thiourea linkage).
are presented as mean ± SD (n =3).
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delivery systems but also served as a stabilizer/emulsifier
to facilitate and stabilize their formation.
The hybrid PLA NPs/MMC-SPC comprised a hydro-
phobic PLA core and an amphiphilic MMC-SPC shell.
Once intravenously administrated, the polymer-lipid
hybrid NPs were accumulated at the tumor site via the
enhanced permeability and retention (EPR) effect. And
then, the polymer-lipid hybrid NPs were internalized by
the cells via endocytosis. Lastly, MMC was released from
the polymer-lipid hybrid NPs and delivered to the nuclei,
presenting the anticancer activity.
The effect of the MMC-SPC concentration on the size,
zeta potential, and encapsulation efficiency of the hybrid
PLA NPs/MMC-SPC was investigated. As shown in
Additional file 1: Figure S1 in supporting information,
when the concentration of MMC-SPC increased, the
particle size of the hybrid PLA NPs/MMC-SPC initially
decreased and then increased. It was believed that at the
appropriate MMC-SPC concentration (0.36 mg/mL), the
amount of the amphiphilic MMC-SPC complex was in
the range to able to cover the surface of the hydrophobic
PLA core. However, when the MMC-SPC concentration
was too high, the excess of the MMC-SPC complex
might participate in the self-organization of the large
size, vesicle-like structures (50 to 500 nm) [7,22]. There-
fore, in the following studies, a MMC-SPC concentration
of 0.36 mg/mL was used to prepare the hybrid PLA
NPs/MMC-SPC.
Table 1 shows a comparison of the characteristics (par-
ticle size, particle size distribution, zeta potential, drug
encapsulation efficiency, and drug loading content) of
PLA NPs/MMC-SPC (MMC-SPC not only used as a drug
preparation but also served as an emulsifier) and PLA
NPs/MMC (PVA used as an emulsifier), from which it can
be seen that as emulsifier, SPC had several aspects of ad-
vantages over the traditional PVA. Firstly, the particle size
of the PLA NPs/MMC-SPC was approximately 200 nm
with PDI < 0.200, while the particle size of the PLA NPs/
MMC was approximately 300 nm with PDI > 0.200. It
can be explained that the MMC-SPC complex could
lower the surface energy of the oil-water interface and
thus facilitate/stabilize the NP formulation. Secondly,
the zeta potential of the PLA NPs/MMC-SPC was ap-
proximately −35 mV, while the zeta potential of the
PLA NPs/MMC was found to be about −20 mV. It can
be attributed to the presence of the negative chargeTable 1 Particle size, PDI, zeta potential, drug encapsulatio
NPs/MMC-SPC and PLA NPs/MMC
Particle size (nm) PDI Zeta potential (m
PLA NPs/MMC-SPC 205.3 ± 5.7 0.110 ± 0.021 −36.3 ± 2.9
PLA NPs/MMC 327.1 ± 12.9 0.320 ± 0.047 −18.7 ± 1.5
Data are presented as mean ± SD (n =3).from the phosphorous group in the SPC molecule.
Lastly, to prepare the NPs with the similar drug encap-
sulation efficiency (to easily compare the drug loading
content of the two formulations, we made the drug en-
capsulation efficiency for the two formulations about
equal by varying the weight of the input drug, lipid, and
polymer), the drug loading content of the PLA NPs/
MMC-SPC was approximately sixfold higher that of the
PLA NPs/MMC. MMC-SPC may serve as a function of
the structural element of the nanoscaled drug delivery
systems, providing a significant higher retaining of the
loaded drug.
As it is reported, a particle size (200 to 300 nm) may
be suited for the EPR effect [39,40], providing a passive
targeting. A high zeta potential (lower than −30 mV or
higher than 30 mV) can provide an electrostatic repul-
sion to avoid the aggregation of the particles [41]. A high
drug loading content is essential for intravenous admin-
istration, which will reduce the dosage of carriers and
the possible side effects to the patients [42,43]. Thus,
SPC had much higher emulsification efficiency than PVA.
Moreover, SPC was a natural product, and the PVA was
a chemical. The former can thus cause less side effects
than the latter. All of the results demonstrated a pro-
spect of the useful nanoscaled drug delivery systems
(PLA NPs/MMC-SPC) with a nanoscaled particle size, a
narrow particle size distribution (Figure 2A and Table 1),
a high zeta potential (Figure 2B and Table 1), a spherical
shape (Figure 2C,D), a well-stability (Figure 2E, discussed
as below) and a high drug loading content (Table 1) for
drug delivery.
In vitro stability
The clinical use of the PLA NPs as intravenous drug deliv-
ery systems is limited due to their poor physiological stabil-
ity. We thus investigated if the hybrid PLA NPs/MMC-SPC
can overcome this drawback. As shown in Figure 2E, the
hybrid PLA NPs/MMC-SPC exhibited a structural stabil-
ity under physiological conditions as demonstrated by no
significant particle size change over 48 h. We speculated
that the presence of the phospholipid complex on the sur-
face of the hybrid PLA NPs/MMC-SPC prevented the ag-
gregation of the nanoscaled drug delivery systems.
In vitro drug release
The in vitro drug release profiles of the PLA NPs/MMC-
SPC and PLA NPs/MMC were monitored as a function ofn efficiency, and drug loading content of the PLA
V) Drug encapsulation efficiency (%) Drug loading content (%)
37.6 ± 2.9 10.3 ± 2.4
34.5 ± 3.8 1.7 ± 0.4
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released from the PLA NPs/MMC-SPC is no more than
30% over 12 h, whereas that of MMC released from the
PLA NPs/MMC is approximately 50%. The result indi-
cated that the PLA NPs/MMC-SPC were more efficient
than the PLA NPs/MMC in reducing the premature burst
release (minimizing the initial drug release in the blood
circulation). The difference was possibly due to the fact
that both the hydrophobic interaction of PLA polymer
molecules and SPC lipid molecules and the electrostatic
interaction of SPC lipid molecules and MMC drug mole-
cules conferred the effective integrity of the hybrid PLA
NPs/MMC-SPC. The MMC-SPC complex trapped on the
surface of the hybrid NPs would suffer the dissociation,
and subsequently, MMC as a free form could diffuse from
the hybrid NPs. We believed that the introduction of
drug-phospholipid complex which not only acted as a
bridge of drug loading but also served as a control of drug
release, could endow the drug not only to increase the
drug loading content but also to prolong the drug release
period, which might actually contribute to the improved
therapeutic efficacy and the reduced side effects.
In vitro cellular uptake
We selected H22 cell as the model to evaluate the cellular
uptake of the coumarin-6-labeled PLA NPs/MMC-SPC
and PLA NPs/MMC at the equivalent concentration of
coumarin-6 using confocal laser scanning microscopy.
To better compare the cell internalization among the
coumarin-6-PLA NPs/MMC-SPC and coumarin-6-PLA
NPs/MMC, the images were taken by harmonizing the
parameters such as laser power, sensitivity, offset, andFigure 3 In vitro drug release of the hybrid PLA NPs/MMC-SPC. Time-d
and free MMC in PBS at pH 7.4. Data are presented as mean ± SD (n =3).gain constant during the cell imaging procedure. As
shown in Figure 4A, the green fluorescence was ob-
served within H22 cells after 6 h of incubation, indicat-
ing the internalization of the PLA NPs/MMC-SPC and
PLA NPs/MMC. More importantly, the significantly
higher fluorescence intensity was observed in the cyto-
plasm of H22 cells treated with the coumarin-6-PLA
NPs/MMC-SPC compared to those treated with the
coumarin-6-PLA NPs/MMC with the same incubation
time under the identical instrumental conditions. The
result can be explained by the existence of SPC on the
surface of the hybrid PLA NPs/MMC-SPC. Since SPC
was an amphiphilic molecule composing of a hydro-
philic head and a hydrophobic tail and also was similar
to the phospholipids of the cell membrane in the struc-
ture component; thus, the cellular uptake of the hybrid
PLA NPs/MMC-SPC was facilitated by the mutual
interaction between the hybrid PLA NPs/MMC-SPC
and the cell membrane.
Flow cytometry
To more precisely understand how the composition of
formulations affected the cell internalization of the NPs,
H22 cells were incubated with the coumarin-6-PLA NPs/
MMC-SPC and coumarin-6-PLA NPs/MMC and subse-
quently analyzed the cells by flow cytometry. As clearly
shown in Figure 4B, both the coumarin-6-PLA NPs/
MMC-SPC and coumarin-6-PLA NPs/MMC indeed
showed a time-dependent cell uptake. The cellular up-
take of the coumarin-6-PLA NPs/MMC-SPC was not
significantly different from that of the coumarin-6-PLA
NPs/MMC-SPC after incubation of 0.5 h. In contrast,ependent drug release from the PLA NPs/MMC-SPC, PLA NPs/MMC,
Figure 4 In vitro cellular uptake of the hybrid PLA NPs/MMC-SPC. (A) Confocal laser scanning microscopy images of H22 cells incubated with
the (a, b, and c) coumarin-6-PLA NPs/MMC-SPC and (d, e, and f) coumarin-6-PLA NPs/MMC at the equivalent coumarin-6 concentration for 6 h
at 37°C. (a and d) Left column showed the blue fluorescence from the cell nuclei (the cell nuclei were stained with Hoechst 33258 (Sigma-Aldrich,
St. Louis, MO, USA)). (b and e) Middle column showed the green fluorescence from the NPs (the NPs were labeled with coumarin-6). (c and f)
Right column is the merged picture of the left column and right column. All the scale bars represented 25 μm. All images were taken under identical
instrumental conditions. (B) Flow cytometer tests of H22 cells incubated with the coumarin-6-PLA NPs/MMC-SPC and coumarin-6-PLA NPs/MMC
(equivalent coumarin-6 concentration) for 0.5, 1.5, and 4.5 h. Data are presented as mean ± SD (n =3). *P < 0.05 (two-tailed Student's t-test).
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SPC was significantly higher than that of the coumarin-
6-PLA NPs/MMC after incubation of 1.5 and 4.5 h. The
different phenomenon could be explained by cell penetra-
tion rate of the nanoscaled drug delivery systems depend-
ing on the NP concentration differences between the
internal and external environment of the cell membraneor the interaction of the NPs and the cell membrane. It
should be concluded that in the case of the incubation of
a short period of time, the NP concentration differences
between the internal and external environment of the cell
membrane played a main role in the cell penetration rate
of the nanoscaled drug delivery systems; however, in the
case of the incubation of a long period of time, the
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vital role.
Consistent with the observations by confocal laser scan-
ning microscopy, the result of flow cytometry confirming
that enhanced cellular internalization (45.6% increased for
4.5 h) of the PLA NPs/MMC-SPC compared with the
PLA NPs/MMC. The lipophilicity and liposolubility of
SPC on the surface of the hybrid PLA NPs/MMC-SPC
perhaps increased the endocytosis and facilitated the pas-
sive delivery of the PLA NPs/MMC-SPC NPs to the inter-
ior of the cells.
Intracellular drug delivery
The fate of MMC after entering the cell is important for
subsequent induction of cell death/apoptosis in the nu-
clei [44,45]. To investigate whether the MMC molecules
loaded within the hybrid PLA NPs/MMC-SPC could be
transported to the nuclei, H22 cells were treated with the
PLA NPs/FITC-MMC-SPC, and the intracellular drug
delivery is shown in Figure 5. The blue fluorescence
resulting from the Hoechst 33258 (Sigma-Aldrich, St.
Louis, MO, USA) staining served to label the nuclei, the
red fluorescence resulted from the rhodamine-phalloidin
staining served to label the cytoskeleton, and the green
fluorescence represented the FITC-MMC.
For both the PLA NPs/FITC-MMC-SPC and PLA NPs/
FITC-MMC, the green fluorescence was presented in the
cell. This finding was similar to the reported work [46]. ItFigure 5 Intracellular drug delivery of the hybrid PLA NPs/MMC-SPC.
the (A,B,C) coumarin-6-PLA NPs/FITC-MMC-SPC and (D,E,F) coumarin-6-PL
at 37°C. (A,D) Left column showed the red fluorescence from the cytosk
(B,E) Middle column showed the green fluorescence from the drugs (th
column and middle column is shown in (E,F) right column. The nuclei were swas also reported that the premature released FITC or
FITC-MMC could be not internalized by the cells [37]. To
the result, we proposed two possible reasons, one was that
the intracellular drug release and transport played a dom-
inate role. A part of drug was released from the NPs and
transported inside the cells. Alternatively, the other one
was that the intracellular drug accumulation and diffusion
played a main role. A high nuclear accumulation of FITC-
labeled MMC resulted in the subsequent diffusion to
other cytoplasmic areas. Regardless of either mechanism,
the result confirmed that the drug delivered to the nuclei
resulted from the effective cellular uptake, followed by the
efficient intracellular internalization and accumulation of
drug.
It should be noted that, the fluorescence signals of H22
cells incubated with the PLA NPs/FITC-MMC-SPC were
significantly increased compared with those incubated
with the PLA NPs/FITC-MMC at the same incubation
time under the identical instrumental conditions, the re-
sult combined with the in vitro cellular uptake further
confirmed that the interaction of SPC on the surface of
the hybrid PLA NPs/FITC-MMC-SPC, and the cell mem-
brane enhanced the cellular uptake of the nanoscaled drug
delivery systems, hence, increased the intracellular intern-
alization and accumulation of FITC-labeled MMC. A suf-
ficient intracellular drug concentration was essential for
an enhanced anticancer activity. Escape of the delivered
MMC from endo/lysosome into nuclei was important asConfocal laser scanning microscopy images of H22 cells incubated with
A NPs/FITC-MMC at the equivalent coumarin-6 concentration for 12 h
eleton (the cell nuclei were stained with rhodamine-phalloidin).
e drugs were labeled with FITC). The merged image of the images in left
tained with Hoechst 33258 (Sigma-Aldrich, St. Louis, MO, USA) (blue).
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could interrupt its function. Although more studies were
needed to better understand the nuclear radiolabeled
MMC delivery and the underlying mechanism, the result
did suggest that our NPs were capable of effectively medi-
ating intracellular drug delivery.
In vitro cell viability
The efficacy of the PLA NPs/MMC-SPC to defeat cancer
cells is reflected by their cytotoxicity. As shown in Figure 6,
the PLA NPs/MMC-SPC and PLA NPs/MMC showed
the concentration-dependent cytotoxicity against H22 cells
for 24 h. It was straightforward to understand that the
lower cell viability corresponds to the higher concentra-
tion of drugs. Notably, the PLA NPs/MMC-SPC signifi-
cantly reduced the cell viability compared to the PLA
NPs/MMC at the same drug concentration. As it is re-
ported, the drug-loaded polymer NPs might be internal-
ized by endocytosis due to their nanoscaled particle size
[47]. Nevertheless, owing to the affinity of SPC to cells,
the polymer-lipid hybrid NPs might further enhance the
internalization of drug. Therefore, the result can be as-
cribed to the enhanced cellular uptake of the nanoscaled
drug delivery systems (see Figure 4) and the increased
intracellular accumulation of the drugs (see Figure 5),
which result in the improved anticancer activity.
Besides, the cytotoxicity PLA NPs/MMC-SPC were not
as effective as the free MMC against H22 cells at an
equivalent MMC concentration (Figure 6), which was
most probably because of the prolonged drug release
from the hybrid drug-loaded NPs (see Figure 3). Such a
sustained and prolonged drug release of the PLA NPs/Figure 6 In vitro cell viability of the hybrid PLA NPs/MMC-SPC. Conce
MMC-SPC, PLA NPs/MMC, and free MMC after incubation of 24 h. Data areMMC-SPC might result in the progressive increase of
intracellular drug concentration for cell death. On the
contrary, the free drugs can be rapidly transported into
cells by passive diffuse owing to the driving force of a
pH and concentration gradient and directly inhibit the
cell growth without the drug release [46]. Although the
PLA NPs/MMC-SPC induced a decline in the cytotox-
icity of MMC, the introduction of the nanoscaled drug
delivery systems could increase the passive targeting
efficiency in vivo (discussed below). Once accumulated
at the tumor site, the polymer-lipid hybrid NPs as a
whole would easily into the interior of the tumor cells
to exert the pharmacological effects.
In vivo stability
The in vivo stability of PLA NPs/MMC-SPC was evaluated
by monitoring the blood clearance of the PLA NPs/MMC-
SPC (Figure 7). A hydrophobic near-infrared fluorescent
dye DiR was loaded within the PLA NPs/MMC-SPC as a
probe since the excitation and emission wavelengths of
DiR do not overlap with the autofluorescence of blood,
allowing its concentration to be measured directly from
the whole blood fluorescence [38]. The intravenously
injected DiR-PLA NPs/MMC was rapidly cleared from the
systemic circulation; the fluorescence signal of the DiR-
PLA NPs/MMC in the blood was hardly detectable in as
little as 0.5 h after the intravenous injection, which was
expected based on their rapid aggregations in plasma. In
contrast, the DiR-PLA NPs/MMC-SPC had a slower
clearance profile, indicating that MMC-SPC reduced
the nonspecific interactions with the plasma protein to
some extent. Although more studies are needed to betterntration-dependent cell viability of H22 cells treated with the PLA NPs/
presented as mean ± SD (n = 6). *P < 0.05 (two-tailed Student's t-test).
Figure 7 In vivo blood clearance of the hybrid PLA NPs/MMC-SPC. Rats were intravenously injected with the DiR-PLA NPs/MMC-SPC and
DiR-PLA NPs/MMC. Data are presented as mean ± SD (n = 6).
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suggest that the PLA NPs/MMC-SPC were capable of ef-
fectively enhancing the blood retention in the systemic
circulation.
Ex vivo fluorescence imaging
To reveal the potential of such hybrid NPs as a MMC
delivery system in vivo, near-infrared fluorescent probe
DiR was incorporated into the PLA NPs/MMC-SPC.
Mice bearing murine hepatoma H22 tumor were intra-
venously administrated with DiR-PLA NPs/MMC-SPC
via the lateral tail vein. The ex vivo biodistribution of the
DiR-PLA NPs/MMC-SPC micelles was then investigated
at 12 h post-injection. Organs from a control mouse
without injection of the DiR-PLA NPs/MMC-SPC were
collected and used as controls to subtract the autofluo-
rescence background in various tissues. Figure 8A shows
the real-time images of the DiR-PLA NPs/MMC-SPC in
the H22 tumor-bearing nude mice. In vivo imaging showed
that the DiR-PLA NPs/MMC-SPC were clearly observed
in the body, and then, the fluorescent signals gradually
became weaker as the time elapsed. At 12 h post-injection,
the high-intensity fluorescent signals of the DiR-PLA NPs/
MMC-SPC were observed at the tumor site. As shown in
Figure 8B, a relatively strong fluorescence in the liver was
observed compared to other organs, which was likely attrib-
uted to the nonspecific clearance of the NPs by the reticu-
loendothelial system (RES). The result was in agreement
with the report in the literature [48]. In addition, the strong
fluorescence was observed at the tumor site, demonstrating
some accumulation of the DiR-PLA NPs/MMC-SPC in
the tumor tissue. The result could be explained by theparticle size-mediated EPR effect [4,49]. However, on the
basis of the EPR effect, the targeting efficiency of the PLA
NPs/MMC-SPC might be further increased by the func-
tionalization of a long-circulation agent (such as PEG) co-
ordinated with a targeting ligand (such as folate or cRGD).
The relevant studies were still under investigation.
In vivo anticancer effect
Next, we examined the anticancer effect of the PLA
NPs/MMC-SPC after the accumulation at the tumor
site. As shown in Figure 8C, the intravenous injection of
the PLA NPs/MMC-SPC and free MMC inhibited the
tumor growth, whereas the MMC-free PLA NPs/SPC
did not slow the tumor growth. The result showed that
MMC, the delivery of which was mediated by the hybrid
PLA NPs/MMC-SPC, was responsible for the tumor
growth inhibition. More importantly, the tumor growth
of mice treated with the PLA NPs/MMC-SPC was much
slower than that of mice treated with the free MMC,
and the difference became more significant after day 12.
In addition, the loss of body weight in mice accompanied
the treatment with the free MMC in this study (Figure 8D)
but was not found in the treatment with the hybrid PLA
NPs/MMC-SPC. All of the results suggested that com-
pared with the free MMC, the hybrid PLA NPs/MMC-
SPC showed a significantly enhanced therapeutic efficacy
while reducing the side effect of chemotherapy drug.
We concluded that the following reasons might be in-
volved. Firstly, the free MMC is cleared too rapidly, and
thus, the low concentrations of drugs in the tumor tis-
sues will result in suboptimal therapeutic effects [2]. On
the contrary, the EPR effect and the sustained release of
Figure 8 In vivo fluorescence imaging and in vivo anticancer
effect of the hybrid PLA NPs/MMC-SPC. (A) In vivo fluorescence
imaging of H22 tumor-bearing mice after intravenous injection of
the DiR-PLA NPs/MMC-SPC at 1, 3, and 12 h post-injection. (B) Ex vivo
fluorescence imaging of H22 tumor-bearing mice after intravenous
injection of the DiR-PLA NPs/MMC-SPC at 12 h post-injection (Li, liver;
S, spleen; K, kidney; H, heart; Lu, lung; T, tumor). (C) The change of
tumor volumes of H22 tumor-bearing mice treated with PBS, PLA NPs/
SPC, PLA NPs/MMC-SPC, and MMC. (D) The change of body weights of
H22 tumor-bearing mice treated with 0.9% NaCl, PLA NPs/SPC, PLA
NPs/MMC-SPC, and MMC.
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ficient intracellular drug. Secondly, the nanoscaled drug
delivery systems can help the loaded drug effectively en-
ters the interior of cells by endocytosis. Lastly, the lipo-
philicity and liposolubility of SPC on the surface of the
polymer-lipid hybrid NPs efficiently help the NPs trans-
port from the surrounding water-soluble environment to
the lipid-rich cell membrane and enter the internal envir-
onment of the cells, leading to the increased internaliza-
tion and accumulation of drug inside the cells. Therefore,
the present study suggested that after the intravenous ad-
ministration, the hybrid PLA NPs/MMC-SPC were useful
in significantly improving the anticancer effect of MMC
while reducing its toxicity compared to the MMC injec-
tion for clinical treatment.Conclusions
We have developed the MMC-loaded polymer-lipid hy-
brid NPs for sustained and controlled release of MMC by
a single-step self-assembly. The composition of the PLA
NPs/MMC-SPC not only affected their drug release but
also influenced their cellular uptake and anticancer effi-
cacy. We concluded that natural SPC had great advan-
tages over traditional PVA with less burst drug release,
more cellular uptake, and higher anticancer efficacy. The
PLA NPs/MMC-SPC might efficiently ensure the nuclear
delivery of MMC to induce cell death. More importantly,
the PLA NPs/MMC-SPC showed the improved thera-
peutic efficiency compared with the free MMC injection.
All of the results suggested that the MMC-loaded polymer-
lipid hybrid NPs have promising potential as attractive and
practical nanoscaled MMC delivery systems for cancer
therapy.Additional file
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